Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial.
Translational cancer research（2023）
摘要
ClinicalTrials.gov Identifier: NCT04383977. It was registered on May 12, 2020.
更多查看译文
关键词
ovarian cancer,apatinib,platinum-resistant,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要